Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill aims to tackle cholesterol in metabolic syndrome patients

NCT ID NCT07523971

Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a fixed-dose combination of two cholesterol-lowering drugs (Pitavastatin and Ezetimibe) in 10,000 adults with high cholesterol and metabolic syndrome. Researchers will track how much LDL ('bad') cholesterol drops after 24 and 48 weeks of treatment in real-world clinics. The goal is to see if this pill works well and is safe for everyday use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pitavastatin/Ezetimibe combination tablet
What this could lead to
If successful, this could confirm that the combination pill effectively lowers cholesterol in real-world patients with metabolic syndrome, supporting its routine use.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. The study is large but early in real-world testing, and individual responses may vary.
Why investors are watching

JW Pharmaceutical is running a large observational study of its fixed-dose Pitavastatin/Ezetimibe tablet in 10,000 patients with dyslipidemia and metabolic syndrome. For a small-cap company, this real-world readout on cholesterol reduction and safety over 48 weeks could shape how doctors prescribe the drug and how the product competes.

If it works: A positive result could strengthen the drug's position in a crowded cholesterol market and support broader use in routine care. That could help JW Pharmaceutical grow sales of a key product.

If it fails: Observational studies can produce mixed or weak results, and the company has no control over how doctors treat patients. If the data show limited benefit or safety concerns, the product could lose credibility, and the company would have spent resources without a clear payoff.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Dyslipidemia Who Also Have Metabolic Syndrome

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 19 years old at the time of written informed consent 2. Subjects diagnosed with dyslipidemia and metabolic syndrome 3. Subjects who had no treatment history with lipid regulators within 4 weeks prior to Visit1 or who had insufficient therapeutic effects from 8 weeks of treatment with lipid regulators using the same dosage and administration 4. Subjects who meet the following LDL-C levels according to the classification of cardiovascular disease risk groups\* at Visit 1 or who are planned to be treated with Pitavastatin/Ezetimibe Tablets based on the judgment of the investigator 5. Subjects who voluntarily sign the informed consent form for study participation Exclusion Criteria: 1. Individuals for whom Pitavastatin/Ezetimibe Tablets is contraindicated as specified in the label's Precautions for Use 2. Individuals who were treated with other investigational products (IP) or investigational devices within 4 weeks prior to participation in the present study or who are expected to have such treatment during the present study 3. Individuals who are considered to have difficulty participating in the study for other reasons based on the judgment of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemias are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Dyslipidemias hyperlipidemia inherited lipid metabolism disorder metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemias

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chungnam National University Hospita

    RECRUITING

    Daejeon, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.